恩替卡韦治疗后出现病毒学突破的慢性乙型肝炎患者的耐药分析  

Resistance assay in chronic hepatitis B patients who underwent virological breakthrough during entecavir treatment

作　　者：薛瑞霞[1] 张缭云[1] 杨松[2] 王琦[2] 邢卉春[3] 郭江[3] 谢雯[3] 闫杰[3] 成军[2] 

机构地区：[1]山西医科大学第一附属医院感染病科,太原市030000 [2]首都医科大学传染病研究所 [3]北京地坛医院肝病中心

出　　处：《中华实验和临床感染病杂志（电子版）》2009年第2期9-12,共4页Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)

基　　金：首都特色临床医学技术发展研究研发攻关类项目(Z07050700690702);北京市卫生局青年科学研究资助项目(QN2007-47)

摘　　要：目的研究恩替卡韦(ETV)治疗后出现病毒学突破的慢性乙型肝炎(CHB)患者的ETV耐药情况。方法收集10例ETV治疗后出现病毒学突破患者的血清,PCR产物直接测序结合克隆测序法用于ETV耐药检测,NCBI HBV基因型分析软件用于HBV基因型确定。结果10例病毒学突破患者中B基因型者3例,C基因型者7例,其中检出8例ETV基因型耐药。结论PCR产物直接测序结合克隆测序法可以作为目前国内检测ETV耐药的主要手段;rtT184L变异在B或C基因型的ETV耐药患者中较为常见。Objective To investigate the resistance profiles of chronic hepatitis B patients who underwent virological breakthrough during entecavir （ETV） treatment. Methods Ten serum samples of patients who underwent virological breakthrough during ETV treatment were collected. Direct sequencing of PCR products and cloning sequencing were used to determine ETV genotype resistance. NCBI HBV genotyping tool was used for determining HBV genotype. Results Of ten patients with virological breakthrough, 3 were genotype B and 7 were genotype C. Eight were ETV resistance positive. Conclusions Direct sequencing of PCR products and cloning sequencing may be the main methods to determine ETV genotype resistance in China; rtT184L was common in patients with ETV genotype resistance in our study.

关 键 词：慢性乙型肝炎 恩替卡韦 耐药 

分 类 号：R512.6[医药卫生—内科学]